Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Date of authorisation: 26/05/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 22 December 2025 - 14:20

Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Date of authorisation: 26/05/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 22 December 2025 - 14:10

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 22 December 2025 - 14:00

Human medicines European public assessment report (EPAR): Zemcelpro, allogeneic umbilical cord-derived CD34- cells, non-expanded,dorocubicel, Date of authorisation: 25/08/2025, Revision: 1, Status: Authorised

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 14:30 (CEST)

Submitted by Anonymous (not verified) on 22 December 2025 - 9:30

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 14:30 (CEST)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More